Phase 2 N=51 Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Lung Cancer
Primary: Median Progression Free Survival — 7.8 Months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=38 Carboplatin, Pemetrexed Disodium, and Bevacizumab for Patients With Stage III or IV Non-Small Cell Lung Cancer Who Are Light/Never Smokers
Lung Cancer
Primary: Progression-free Survival — 12.6 months
Phase 2 N=13 Bevacizumab, Docetaxel, and Gemcitabine Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Lung Cancer
Primary: Progression Free Survival(PFS) — 5.6 months
Phase 2 N=37 AZD0530 to Treat Recurrent Stage IIIB/IV NSCLC Previously Treated With Combination Chemotherapy
Recurrent Non-small Cell Lung Cancer · Stage IIIB Non-small Cell Lung Cancer · Stage IV Non-small Cell Lung Cancer
Primary: Rate of Disease Control (Freedom From Disease Progression) — 4 participants
Phase 2 N=37 Phase II Study of Abraxane and Gemicitabine in Patients With Advanced Adenocarcinoma Non-Small Cell Lung Cancer Progressing After First-Line Platinum-Based Chemotherapy
Patients With Stage IV or Recurrent Adenocarcinoma of the Lung
Primary: Overall Response Rate — 13.5 percentage of participants
Phase 2 N=74 Gefitinib and Everolimus in Treating Patients With Stage IIIB or Stage IV or Recurrent Non-Small Cell Lung Cancer
Lung Cancer
Primary: Overall Objective Response — 1; 1; 3; 2 participants
Phase 3 N=939 Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer
Non Small Cell Lung Cancer
Primary: Progression Free Survival (PFS) — 2.89; 2.76; 2.37; 1.54 months — p=0.756
Phase 2 N=71 Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Lung Cancer
Primary: Mediastinal Nodal Clearance After Completion of Induction Chemoradiotherapy With or Without Panitumumab. — 68.2; 48.7 percentage of participants — p=0.96
Phase 2 N=79 Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer
Bronchioloalveolar Carcinoma · Large Cell Lung Carcinoma · Lung Adenocarcinoma
Primary: PFS (Progression Free Survival) — 8; 20 months
Phase 2 N=86 Erlotinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Lung Cancer
Primary: Overall Response Rate — 18; 34; 28 percentage of participants
Phase 2 N=46 Preoperative Pemetrexed and Carboplatin for Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer
Non Small Cell Lung Cancer
Primary: 3-Year Overall Survival Rate — 45 percentage of participants
Phase 2 N=3 Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer
Metastatic Lung Non-Squamous Non-Small Cell Carcinoma · Recurrent Lung Non-Squamous Non-Small Cell Carcinoma · Stage IV Lung Non-Small Cell Cancer AJCC v7
Primary: Progression-free Survival (PFS) — 6.35; 14.3 months
Phase 2 N=63 Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Lung Cancer
Primary: Overall Response Rate Defined as Complete or Partial Response as Assessed by RECIST Version 1.0 Criteria. — 38.1; 0 percentage of patients
Phase 3 N=720 PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer
Lung Cancer
Primary: Overall Survival — 6.83; 6.31 Months — p=0.506
Phase 1 N=14 Nintedanib and Weekly Docetaxel in Lung Adenocarcinoma
Carcinoma, Non-Small-Cell Lung
Primary: Maximum Tolerated Dose (MTD) of Nintedanib Administered in Combination With Docetaxel — NA milligram
Phase 2 N=37 BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer
Non-Small-Cell Lung Carcinoma
Primary: Response Rate — 6 percentage of participants
Phase 2 N=82 Ixabepilone and Carboplatin +/- Bevacizumab in Advanced Non-Small-Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment — 29; 50 percentage of participants
Phase 3 N=168 S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer
Recurrent Non-Small Cell Lung Carcinoma · Stage IV Non-Small Cell Lung Cancer
Primary: 2-year Overall Survival Rate — 67; 70 percentage of participants — p=0.44
Phase 2 N=62 Pemetrexed, Carboplatin, and Bevacizumab as First-Line Therapy in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Lung Cancer
Primary: Progression-free Survival at 6 Months — 60 percentage of participants
Phase 2 N=50 Bevacizumab (Avastin®) + Erlotinib as First-line Therapy for Stage IIIB/IV or Recurrent, Non-squamous Cell Lung Cancer
Cancer
Primary: Evaluation of Overall Survival — 50.4 weeks
Phase 2 N=72 Cetuximab in Treating Patients With Recurrent or Stage IIIB or Stage IV Lung Cancer
Lung Cancer
Primary: Objective Response Rate (Proportion of Patients With Objective Response) — 0.07 Proportion
Phase 2 N=105 Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer
Primary: Progression Free Survival (PFS) at 18-month — 65.5; 66.3 Percentage of participants
Phase 2 N=32 Anti-angiogenesis Agent AG-013736 in Patients With Advanced Non-Small Cell Lung Cancer
Lung Neoplasms · Carcinoma, Non-small Cell Lung
Primary: Percentage of Participants With Objective Response (OR) — 9.4 Percentage of participants
Phase 2 N=60 AZD2171 and Pemetrexed Disodium in Treating Patients With Relapsed Non-Small Cell Lung Cancer
Recurrent Non-small Cell Lung Cancer
Primary: Response Rate (Complete and Partial) 2 Separate Cohorts of Relapsed NSCLC Cohort A: Pts Who Have Received Prior Chemo w/o Ever Having Received Bevacizumab. Cohort B: Pts…
Phase 4 N=2,252 A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
Non-Squamous Non-Small Cell Lung Cancer
Primary: Number of Participants With Adverse Events of Special Interest — 687; 672; 26; 30 participants
Phase 2 N=46 Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer
Lung Cancer
Primary: Maximum Dose of Erlotinib When Given Together With Carboplatin, Paclitaxel, and Thoracic Conformal Radiotherapy (Phase I [Closed to Accrual as of 1/3/2008]) — 0; 0; 2 DLTs
Phase 2 N=39 Lower Dose Chemotherapy Given More Frequent With Avastin to Treat Advanced Non-Squamous Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) — 8.5 months
Phase 2 N=66 E7389 in Treating Patients With Recurrent or Progressive Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Recurrent Non-small Cell Lung Cancer · Stage IIIB Non-small Cell Lung Cancer · Stage IV Non-small Cell Lung Cancer
Primary: Objective Response Rate (CR or PR) According to RECIST Criteria — 5 percentage of patients responding
Phase 2 N=133 Chemotherapy With Pemetrexed in Combination With Platinum for Advanced Non-Small Cell Lung Cancer (NSCLC)
Non-Small-Cell Lung Cancer
Primary: Percentage of Participants Surviving Progression-Free at 6 Months (Progression Free Survival [PFS] Rate) — 52.8; 39.3 percentage
Phase 2 N=16 Pemetrexed Disodium in Treating Patients With Stage IV Non-small Cell Lung Cancer and ECOG Performance Status 3
Stage IV Non-Small Cell Lung Cancer
Primary: Change in Quality of Life (QOL), Assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (QLQ-C30) and QLQ-Lung…